Lung cancer screening provides an opportunity for early diagnosis and treatment of interstitial lung disease
Abstract
Interstitial lung abnormalities (ILA) can be incidentally detected in patients undergoing low-dose CT screening for lung cancer. In this retrospective study, we explore the downstream impact of ILA detection on interstitial lung disease (ILD) diagnosis and treatment. Using a targeted approach in a lung cancer screening programme, the rate of de novo ILD diagnosis was 1.5%. The extent of abnormality on CT and severity of lung function impairment, but not symptoms were the most important factors in differentiating ILA from ILD. Disease modifying therapies were commenced in 39% of ILD cases, the majority being antifibrotic therapy for idiopathic pulmonary fibrosis.Keywords
This publication has 8 references indexed in Scilit:
- Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisationLung Cancer, 2020
- Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research prioritiesThe Lancet Respiratory Medicine, 2020
- Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner SocietyThe Lancet Respiratory Medicine, 2020
- Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized TrialNew England Journal of Medicine, 2020
- Interstitial lung abnormalities in the Queensland Lung Cancer Screening Study: prevalence and progression over 2 years of surveillanceInternal Medicine Journal, 2018
- Interstitial Lung Abnormalities in a CT Lung Cancer Screening Population: Prevalence and Progression RateRadiology, 2013
- Selection Criteria for Lung-Cancer ScreeningNew England Journal of Medicine, 2013
- The LLP risk model: an individual risk prediction model for lung cancerBritish Journal of Cancer, 2007